Clinical trials: Topotecan
Lung Cancer
Concurrent Radiotherapy With Weekly Topotecan for Primary Treatment of Inoperable Localized Non-small Cell Lung Cancer
Given the activity of single-agent Topotecan in NSCLC, there is both scientific rationale and a medical interest in studying this agent in combination with radiation.
- Trial name
- NCT00322751
- Testing
- Topotecan
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of New Mexico
Ovarian Cancer
Topotecan With Erlotinib for Topotecan Pretreated Ovarian Cancer
This is a single arm phase II study with a combination of Hycamptin® (topotecan) and erlotinib for a minimum of 2 cycles in patients (18 yrs of age and older) with recurrent ovarian cancer previously treated with chemotherapy…
- Trial name
- NCT01003938
- Testing
- Topotecan, Erlotinib
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- NYU Langone Health
Leukemia
Chemotherapy in Treating Children With Relapsed Acute Leukemia, Acute Myeloid Leukemia, or Blastic Phase Chronic Myelogenous Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of topotecan in treating children who have relapsed acute…
- Trial name
- NCT00003735
- Testing
- topotecan hydrochloride
- Where
- 38 sites in United States, Australia and 1 more
- Volunteers
- 11 people
- Sponsor
- Children's Oncology Group
Ovarian Cancer
Pertuzumab in Platinum-Resistant Low Human Epidermal Growth Factor Receptor 3 (HER3) Messenger Ribonucleic Acid (mRNA) Epithelial Ovarian Cancer (PENELOPE)
This two-part, multicenter study will evaluate the safety, tolerability and efficacy of pertuzumab in combination with standard chemotherapy in women with recurrent platinum-resistant epithelial ovarian cancer.
- Trial name
- NCT01684878
- Testing
- Gemcitabine (Chemotherapy), Paclitaxel (Chemotherapy), Pertuzumab
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 208 people
- Sponsor
- Hoffmann-La Roche
Ovarian Cancer
Topotecan Weekly Versus Topotecan Day 1-5 in Patient With Platin-resistant Ovarian Cancer
Comparison of topotecan weekly vs. topotecan day 1-5. The compatibility and activity are to be examined.
- Trial name
- NCT00170677
- Testing
- Topotecan
- Where
- Germany
- Volunteers
- 194 people
- Sponsor
- North Eastern German Society of Gynaecological Oncology
Ovarian Cancer, Fallopian Tube Cancer
Ph II Study of Wkly Topotecan + Bevacizumab in Plat. Resistant/Recurrent Gyn Cancers
The purpose of this study is to evaluate the clinical safety and toxicity of intravenous bevacizumab (Days 1 and 15 of a 28 day cycle) in combination with weekly topotecan (Days 1, 8, 15 of a 28 day cycle) in patients with…
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT00343044
- Testing
- Topotecan, Bevacizumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Benaroya Research Institute
Pediatric Cancer, Li-Fraumeni Syndrome
Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer
This prospective, single-arm, multi-center clinical trial aims to explore and evaluate the efficacy and safety of arsenic trioxide combined with chemotherapy for pediatric cancer with p53 mutation.
- Conditions
- Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations
- Trial name
- NCT06088030
- Testing
- Arsenic trioxide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yang Li
Fallopian Tube Cancer, Ovarian Cancer
Topotecan in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00114166
- Testing
- topotecan hydrochloride
- Where
- 78 sites in United States
- Volunteers
- 81 people
- Sponsor
- Gynecologic Oncology Group
Cervical Cancer
Topotecan, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as topotecan and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00287911
- Testing
- cisplatin, topotecan hydrochloride, brachytherapy
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Recurrent Small Cell Lung Carcinoma
Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer
The purpose of this study is to evaluate how OSI-906 compares to Topotecan in trying to slow down the growth and/or progression of the tumors of participants with relapsed or recurrent Small Cell Lung Cancer.
- Trial name
- NCT01533181
- Testing
- Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study
- Where
- 11 sites in United States, Singapore
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- FORWARD I (NCT02631876)
- Testing
- Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin
- Where
- 131 sites in United States, Belgium and 11 more
- Volunteers
- 366 people
- Sponsor
- ImmunoGen, Inc.
Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma
Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
This phase I/II trial studies the side effects and best dose of iberdomide when given together with chemoimmunotherapy drugs and to see how well it works in treating patients with neuroblastoma that has come back after a period…
- Conditions
- Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Ganglioneuroblastoma, Refractory Neuroblastoma
- Trial name
- NCT07437963
- Testing
- Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography
- Where
- 2 sites in United States
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Small Cell Lung Cancer
Trial of pasireotideLAR and Topotecan in Relapsed or Refractory Small Cell Lung Cancer
The majority of small cell lung cancer(SCLC)(50-100%) express somatostatin receptors(type 1-5) with some small cell lung cancer express more than one subtypes.
- Trial name
- NCT01417806
- Testing
- Topotecan and Pasireotide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- South Florida Veterans Affairs Foundation for Research and Education
Genital Neoplasms, Female
A Phase I Study of CCI-779 (Temsirolimus) in Combination With Topotecan in Patients With Gynecologic Malignancies
The aim of the trial is to determine the recommended phase II dose of weekly intravenous topotecan in combination with a fixed dose (25 mg or 15 mg) of weekly intravenous temsirolimus in patients with and without prior pelvic…
- Trial name
- NCT00523432
- Testing
- Topotecan, CCI-779 (temsirolimus)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Chicago
Cervical Cancer
Phase II Study of Pazopanib and Topotecan in Cervical Cancer
The goal of this clinical research study is to learn if the combination of topotecan and pazopanib can help to control recurrent cervical cancer. The safety of the study drug combination will also be studied.
- Trial name
- NCT02348398
- Testing
- Pazopanib, Topotecan, Phone Call
- Sponsor
- M.D. Anderson Cancer Center
Myelosuppression Adult, Chemotherapeutic Toxicity
Expanded Access to Trilaciclib for Patients Receiving Chemotherapy for Small Cell Lung Cancer
The purpose of this expanded access protocol is to provide access to trilaciclib for chemotherapy-induced myelosuppression in patients receiving chemotherapy as a treatment for small cell lung cancer (SCLC).
- Conditions
- Myelosuppression Adult, Chemotherapeutic Toxicity, Small Cell Lung Cancer
- Trial name
- NCT04504513
- Testing
- Trilaciclib
- Sponsor
- G1 Therapeutics, Inc.
Retinoblastoma, Retinal Neoplasm
Study of Treatment for Patients With Cancer of the Eye -Retinoblastoma
Retinoblastoma is a childhood cancer which affects the retina of the eye. The retina is the light sensitive layer of tissue that lines the back of the eyeball; sends visual messages through the optic nerve to the brain.
- Trial name
- NCT00186888
- Testing
- Enucleation, Vincristine, Carboplatin, Focal Therapies
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- St. Jude Children's Research Hospital
Lung Cancer
Combination Chemotherapy and Radiation Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033696
- Testing
- filgrastim, carboplatin, etoposide
- Where
- 51 sites in United States
- Volunteers
- 65 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Endometrial Carcinoma, Ovarian Carcinoma
Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)
This trial is a Phase 1b/2a/3 trial designed to evaluate the safety and efficacy of adding oral AL3818 (Anlotinib, INN: Catequentinib), a Dual Receptor Tyrosine Kinase Inhibitor, to standard platinum-based chemotherapy…
- Conditions
- Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma
- Trial name
- AL3818 (NCT02584478)
- Testing
- AL3818, Paclitaxel, Pegylated Liposomal Doxorubicin (PLD)
- Where
- 41 sites in United States, China and 4 more
- Volunteers
- 294 people
- Sponsor
- Advenchen Laboratories, LLC
Fallopian Tube Cancer, Ovarian Cancer
Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
- Trial name
- NCT00003382
- Testing
- filgrastim, gemcitabine hydrochloride, topotecan hydrochloride
- Where
- 6 sites in United States
- Sponsor
- Gynecologic Oncology Group